Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Neutral +5

Moderna Starts Large Bird Flu Study Despite Earlier HHS Funding Loss

📋 Moderna has initiated a large clinical trial for a bird flu mRNA vaccine in the United States and Britain.

👥 The study plans to enroll approximately 4,000 adults, with the first participants already receiving the shot.

🧬 The vaccine utilizes messenger RNA technology, similar to that used in COVID-19 vaccines.

✅ Earlier research involving 300 healthy adults demonstrated promising safety and immune response results.

⚠️ The trial had been delayed after the U.S. Department of Health and Human Services cut funding for pandemic flu vaccine development last year.

💰 Despite the HHS setback, Moderna secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations.

🎯 Moderna CEO Stéphane Bancel stated the trial is a critical step to strengthen global pandemic preparedness.

🗣️ The funding cuts followed questions from Trump administration officials regarding continued public funding for mRNA vaccines.

❌ HHS reduced mRNA vaccine funding citing that the technology remains under-tested for some uses and does not protect against mutating strains.

🔬 HHS officials claimed mRNA investments in upper respiratory viruses were wound down to reinvest in other more promising technologies.

🧬 Experts note that pandemic-era mRNA vaccines proved safe, effective, and faster to develop than traditional vaccines.

🦠 Additional resources on bird flu are available through Cornell University College of Veterinary Medicine.

📰 This news was reported by The Washington Post on April 21, 2026.

Bullish Signals
  • Moderna has initiated a large clinical trial for a bird flu vaccine with approximately 4,000 adult participants across the United States and Britain.
  • The first participants in this study have already received the vaccine shot, marking immediate progress in pandemic preparedness.
  • Earlier research involving about 300 healthy adults demonstrated promising results for both safety and immune response to the mRNA-based vaccine.
  • Despite a funding setback from HHS, Moderna secured $54.3 million from the Coalition for Epidemic Preparedness Innovations to support development.
  • Moderna CEO Stéphane Bancel emphasized that their platform technology's efficiency and scalability are critical for responding to future global health threats.
  • Experts noted that mRNA vaccines have proven to be safe and effective during the pandemic and can be developed more quickly than traditional vaccines.
  • Even though HHS reduced funding for upper respiratory viruses, officials acknowledged the potential for mRNA technology in other areas such as cancer.
  • The large clinical trial represents an important step toward strengthening global pandemic preparedness against future outbreaks.
Risk Factors
  • Moderna secured only $54.3 million from the Coalition for Epidemic Preparedness Innovations after losing HHS funding.
Full Analysis
Moderna has officially launched a large-scale clinical trial for a bird flu vaccine utilizing messenger RNA technology, marking a significant milestone in pandemic preparedness despite previous funding setbacks. The study is underway in both the United States and Britain, with an anticipated enrollment of approximately 4,000 adults. According to the company, recruitment and initial dosing have already commenced following earlier research that involved about 300 healthy adults, which demonstrated promising results regarding safety and immune response. The initiative proceeded even after the U.S. Department of Health and Human Services (HHS) cut designated funding last year, an action attributed to questions from the Trump administration regarding the continued public financing of mRNA vaccines for upper respiratory viruses. HHS spokesman Andrew Nixon stated that the agency wound down investments because such vaccines do not protect effectively against infections from mutating strains like COVID-19 and flu, citing a "rigorous review" that determined the technology remains under-tested for certain uses. The government has chosen to reinvest in what it views as other more promising technologies, though officials acknowledged mRNA's potential in areas such as cancer treatment. To offset the HHS reduction, Moderna secured up to $54.3 million from the Coalition for Epidemic Preparedness Innovations, a global consortium dedicated to supporting vaccine development efforts. Stéphane Bancel, Moderna's CEO, emphasized that this trial represents a crucial step toward strengthening global pandemic preparedness, noting that the company's platform technology offers critical efficiency and scalability for addressing future health threats. Experts highlighted that mRNA vaccines, having been proven safe and effective during the pandemic, can be developed more rapidly than traditional alternatives, making them valuable tools in responding to emerging viral threats like bird flu.